Where Global Innovation
and Capital Meet
Sectors Consumer University Energy Financial Healthcare Industrial IT Media Services Telecoms Transport The Art of CVC Startups

Page 99

No time wasted as Enerkem files for IPO

The waste conversion company is preparing a $125m initial public offering, with backers including Waste Management of Canada seeking a return on their investment.

Feb 8, 2012

Merrimack to wait longer for IPO

The Fidelity-backed cancer drug developer has postponed its $191m IPO after setting the range, according to reports.

Feb 5, 2012

AVG secures $128m IPO

The computer security firm has raised $128m upon its flotation on NASDAQ, with Intel Capital garnering nearly $12m from the offering.

Feb 5, 2012

Synacor gets ready to access $53m IPO

The internet services company will be floating at between $10 and $12 a share, with Intel Capital among the backers looking to cash in.

Feb 2, 2012

FXall hoping for special effect from IPO

FXall, the electronic trading platform formerly known as FX Alliance, which is backed by a range of financial services firms, will offer its shares at between $13.50 and $15.50 when it floats.

Jan 31, 2012

Verastem gets $55m in IPO treatment

The oncological drug developer backed by the firm of SR One's founder outstrips expectations as it raises $55m from its initial public offering, seeing its price rise after the first day of trading.

Jan 30, 2012

Ceres set to feed on IPO cash

The agricultural and biomass technology firm is looking to raise $100m when it floats, with shareholders including Monsanto set for a return on their investment.

Jan 27, 2012

ChemoCentryx sets range for IPO

GlaxoSmithKline-backed ChemoCentryx is looking to raise up to $64m when it floats, hot on the heels of fellow biopharmaceutical company Verastem.

Jan 26, 2012

Verastem sowing seeds of $46m IPO

The biotechnology researcher, backed by a GlaxoSmithKline-linked venture capital firm, has set the range for its shares for its initial public offering at between $9 and $11.

Jan 17, 2012

© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here